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Toxicology and safety assessment are changing and require new strategies for evaluating risk that are less
depending on apical toxicity endpoints in animal models and relying more on knowledge of the
mechanism of toxicity. This manuscript describes a number of developments that could contribute to this
change and implement this in a stepwise roadmap that can be applied for the evaluation of food and food
ingredients.
The roadmap was evaluated in four case studies by using literature and existing data. This preliminary
evaluation was shown to be useful. However, this experience should be extended by including examples
where experimental work needs to be included. To further implement these new insights in toxicology
and safety assessment for the area of food and food ingredients, the recommendation is that stake-
holders take action in addressing gaps in our knowledge, e.g. with regard to the applicability of the
roadmap for mixtures and food matrices. Further development of the threshold of toxicological concern
is needed, as well as cooperation with other sectors where similar schemes are under development.
Moreover, a more comprehensive evaluation of the roadmap, also including the identiﬁcation of the need
for in vitro experimental work is recommended.
© 2016 ILSI Europe. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Foods and food ingredients encompass a broad spectrum of food
materials, ranging from the relatively simple chemical compounds
at one end of the spectrum to complex whole foods and ingredients
at the other. Food additives and ﬂavourings are largely, but not
exclusively, chemically deﬁned substances that lend themselves to
traditional approaches used in a toxicological assessment. Across
the world, food additives and ﬂavourings are governed by legisla-
tion that includes well-established requirements for the demon-
stration of safety in order for them to be used as ingredients in food
products. Other ingredients used for technological purposes, such
as solvents and enzymes, also have their own legislation or conform
to internationally agreed standards. Many whole foods and char-
acterised food ingredients are deemed safe by way of their, often
traditional, history of use in the human diet. Where such a history
of safe use is absent, the foods or ingredients in question are seen as
‘novel’ and subject to control under novel foods legislation, now in
place in a growing number of countries around the world. It is
noteworthy that the vast majority of novel foods are used in theList of abbreviations
ADI Acceptable Daily Intake
ADME Absorption, Distribution, Metabolism, and Excretion
AOP Adverse Outcome Pathway
CFAs Cetylated fatty acids
CMC Cetyl Myristoleate Complex
CWD Cold Water Dispersion
DSSTox Distributed Structure-Searchable Toxicity
ECM Extra Cellular Matrix
EDI Estimated Daily Intake
GI Gastro-Intestinal tract
HACCP Hazard Analysis of Critical Control Points
hESC Human Embryonic Stem Cells
HPLC High Performance Liquid Chromatography
iPSC Induced Pluripotency Stem Cells
mES Mouse Embryonic Stem Cells
MoA Modes of Action
MoS Margin of Safetyform of ingredients. Although there are differences of detail be-
tween novel foods legislation in different countries, they are rela-
tively consistent in their approach to the evidence required to
demonstrate safety. To this end, guidance on safety assessment of
novel foods, including genetically modiﬁed organisms (GMOs) has
been published by various international authorities, e.g. The United
States Food and Drug Administration (1992), OECD (1993), Health
Canada (1994), FAO/WHO (1996), European Commission (1997),
Howlett et al. (2003).
Although foods and food ingredients make up the most signif-
icant part of the daily diet it should be remembered that none are
without some level of risk. Some ingredients may be hazardous in
high concentrations, they may elicit allergic responses in some
individuals, they may accumulate in the body, and they may
include chemicals (Dreisig et al., 2013) that could be the cause of
adverse effects due to long-term low-concentration exposure.
Further, they may modulate adaptive processes, or they may
interact with compounds from other sources and routes leading to
adverse health conditions. For risk assessment of foods and food
ingredients, it is desirable to identify possible toxic compounds alsoMoE Margin of Exposure
NCGC US National Clinical Guideline Center
NGF Neural Growth Factor
NOAEL No Observable Adverse Effect Level
PBBK Physiologically-Based Biokinetics Models
PAHs Polycyclic Aromatic Hydrocarbons
PCBs Polychlorobiphenyls
PoD Point of Departure
PoT Pathways of Toxicity
QD Quantum Dots
(Q)IVIVE (Quantitative) in vitro-in vivo Extrapolation
(Q)SAR (Quantitative) Structure-Activity Relationship
(Q)SPR (Quantitative) Structure-Property Relationships
RDI Reference Daily Intake
SCFE Supercritical Carbon-dioxide Fluid Extraction
TNF Tumor Necrosis Factor
TT21C Toxicity Testing in the 21st Century
TTC Threshold of Toxicological Concern
Table 1
A global description of the current practices in food safety assessment comprise the following elements (Howlett et al. 2003).
1. Depending on the purpose of the assessment and depending on the source of food different categories of food can be recognised:
- single ingredients, ranging from simple to complex
- whole foods
- GM foods (plant or animal origin)
- irradiated foods
- etc.
2. Steps taken in the collection of data (i.e. before any testing):
- purpose of assessment: how is food used?, etc.
- interrogation of data bases
- description of food: origin, composition, nutritional characteristics; chemical analysis as required.
- known potential hazards, e.g. by comparing with similar foods
- for novel foods, GM foods: is there a traditional comparator?
- identify differences from comparator
3. Testing: initial screening of key endpoints:
- in silico and in vitro methods
- for single ingredients: QSAR/read across methods
- protein allergenicity checks
- protein stability
- mutagenicity (Ames test), clastogenicity test
4. Toxicity tolerance tests, animal tests:
- palatability (determine max % that can be incorporated)
- diet formulation to balance for nutrient content
- ADME/PBPK
- single and repeated dosing
- sub-acute toxicity (if needed for target population)
- for GMO: 28 day study in mouse
- 90 day sentinel study in rat
- case by case: Speciﬁc studies addressing speciﬁc endpoints and target populations/target organs/evidence for adverse or nutritional effect, dose-effect relationship?
5. Human studies (target population):
- volunteer study to conﬁrm tolerance
- any unexpected or unintended effects: adjust intended exposure?
6. Hazard characterisation:
- understanding toxicity/nutritional effect: mode-of action, Adverse Outcome Pathway (AOP), dose-effect
- is there a reliable NOAEL
7. Exposure assessment:
- use of EU data bases and product patterns to estimate mean and 97.5 percentile
- take into account sensitive populations: need for labelling requirements?
8. Risk/safety assessment:
- use MOS in context of intended use
- need for post launch monitoring?
B.J. Blaauboer et al. / Food and Chemical Toxicology 91 (2016) 19e35 21on the basis of their chemical structure and mechanism of action
(Daneshian et al., 2013). Moreover, it is desirable to describe
concentration-dependent effects, long-term low-concentration
exposure effects as well as a proper risk-beneﬁt analysis.
In Table 1 an overview is presented of the elements taken into
account in the current common practices applied to the safety
assessment of foods and food ingredients. Whereas the safety
assessment of food additives, for example, follows a well-
established pattern, the assessments of complex foods and in-
gredients have to be approached on a case-by-case basis, depend-
ing very much on the nature and intended use of the food in
question and the speciﬁc questions to be answered. While the
important ﬁrst step is a thorough characterisation and detailed
chemical and nutritional analysis of the food, from Table 1 it is
evident that thereafter there is strong reliance on the interpretation
of animal toxicology studies in the absence of other relevant
models or methods. Other elements consist of methods based on
comparison with existing data on similar compounds or products
making use of the read-across techniques, a number of in vitro
methods, e.g. genotoxicity (where practical), protein stability
(GMOs), etc. Where these are available additional data on the safety
or toxicity after human exposure should also be considered. The
end result is based on an evaluation of the Margin of Safety (MoS)
or Margin of Exposure (MoE) for the intended use in a product.
The safety assessment of foods and ingredients is clearly much
more complicated than for well-characterised, non-food sub-
stances, e.g. industrial chemicals, plant protection products ormedicines. Food additives and ﬂavourings may have more simi-
larities to the aforementioned examples, but the majority of food
ingredients, including GMOs, present a greater challenge, e.g.
because of the complexity of the food composition (Palafox-Carlos
et al., 2011). This diversity of foods is recognised in the legislative
approach adopted internationally and the principle that safety
assessment should be approached on a case-by-case basis is
embodied in the guidelines published by different expert groups.
Furthermore, it is widely recognised that traditional approaches to
hazard and risk assessment applied to deﬁned chemicals, including
food additives, cannot be applied directly to novel foods that are
more complex in nature. The more complex the food, the more
challenging this becomes. For example, the traditional toxicological
approach of setting an acceptable daily intake (ADI), that typically
includes a one hundredfold safety marginwhen compared with the
lowest no observable adverse effect level (NOAEL) seen in toxi-
cology studies, is not feasible for the majority of novel foods.
Complete freedom from risk is an unattainable goal and the cir-
cumstances and degree of exposure to the food in question is an
important consideration. The OECD (1993) proposed that ‘safety’
equates to ‘a reasonable certainty that no harm will result from
intended uses under the anticipated conditions of consumption’.
In all cases, the ﬁrst step is establishing thorough characterisa-
tion of the food. For a novel food this includes its source, method of
production, compositional analysis, including nutrients and
possible contaminants, known toxins or anti-nutritional com-
pounds. This information should permit direct comparison with a
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modiﬁed crops. Intended mode of use as human food and any
history of previous human consumption also form part of this
preliminary set of information. In some cases, e.g. the introduction
of a new food which has a history of traditional consumption
elsewhere in the world, the information outlined above may be
sufﬁcient to complete the safety assessment. The existence of a
known counterpart gives the most important reference point with
which to compare the novel food, both in terms of composition and
when testing in animals may be required. It is particularly relevant
in the case of foods from GM crops and may also apply in other
cases, e.g. a novel process applied to improve the production of an
existing food. Where no traditional counterpart exists and when
toxicological testing in animals is deemed necessary, an existing
food with a similar, though rarely identical, nutritional proﬁle is
normally chosen as a point of comparison. For example, a novel
food expected to be a source of protein in the human diet may be
compared with a protein such as casein (milk protein) or with
another appropriate dietary source of protein.
Undertaking toxicology studies in laboratory animals as part of
the safety assessment of complex novel ingredients or whole foods
may be challenging (Paparella et al., 2013). Whether such studies
are necessary and relevant has to be judged on a case-by-case basis
and is dependent on a number of factors, including information
derived from its characterisation and whether the novel food or its
source have any history of use in the human diet.
The traditional approach when testing chemicals in animal
studies is to add a range of concentrations of the test substance to
an already complete diet appropriate for the test animal in ques-
tion. Because the amounts of test substance added are physically
small, they should have little or no signiﬁcant impact on the
nutritional balance of the diet, thereby affording a simple com-
parison between the control and test diets employed. In other
words, differences in response between the test groups are likely to
be of toxicological origin rather than being due inadvertent nutri-
tional differences, with the exception of effects on food intake
caused by palatability of the test substance. This approach may not
be appropriate for safety testing of complex foods where adding
them to the test diets at high enough levels relevant for desired
human exposure, could both upset the range and balance of nu-
trients provided by the diet. It is vital to eliminate, as far as possible,
such unwanted nutritional differences, so that observed effects can
be interpreted from a toxicological perspective rather than being
confounded, or even hidden, by nutritional effects. With a detailed
knowledge of the nutritional analysis of the novel food and of the
other dietary ingredients to be used, control and test diets can be
formulated to be equivalent in their contents of major and minor
nutrients considered to be of nutritional importance. This approach
is recommended throughout a programme of animal testing and
the nutrient standards employed should be appropriate for the age
and physiological state of the species, e.g. growth vs. reproduction.
In all cases where animal studies are deemed necessary, it is
probable that a 90 day rodent study will be a common requirement
and this may, in some instances, indicate the need for further tar-
geted studies to be undertaken. In vitro systems may be suitable for
certain nutrient availability assays, but in vitro toxicology assays,
e.g. genotoxicity, present many difﬁculties when applied to com-
plex foods, both in terms of execution and interpretation.
In all cases of chemically deﬁned substances or simple mixtures
thereof, it may be possible to follow the traditional toxicological
approach of feeding sufﬁciently high quantities to identify the
NOAEL and to apply a safety factor of 100 in order to establish an
ADI. However, when considering chemically deﬁnable compounds
with a nutritional effect, e.g. new sources of vitamins, minerals and
similar types of compounds, the gap between the amount requiredfor the intended nutritional effect and the level where adverse
nutritional effects occur is often quite narrow and a different
approach is needed.
For more complex novel food ingredients and whole foods, the
ADI approach may not be possible. The proportion of the food that
it is possible to include in a test diet is limited by the maintenance
of nutritional balance, though it may still be physically quite high.
In the absence of observed toxic effects a traditional ADI cannot be
established and a different approach is required. Howlett et al.
(2003) proposed that the highest safe intake identiﬁed in feeding
studies should be compared with the expected human consump-
tion, i.e. the estimated daily intake (EDI), to arrive at a margin of
safety.
When the absence of adverse health effects has been sufﬁciently
established, the option of studies in human volunteers becomes
available to conﬁrm the safety, including absence of adverse re-
actions; to demonstrate the nutritional suitability for purpose and
for population sub-groups. In some cases, these studies may be
supplemented by post launch monitoring to provide further reas-
surance within the totality of the accumulated information on the
novel food in question. Data from human studies may also
contribute to the establishment of safe levels of intake discussed
above, providing additional reassurance to the safety assessment.
2. Scope of this paper
In the light of the new developments in toxicological and safety
research in general, particularly with regard to the need for better
understanding of the safe use of foods, this manuscript presents an
overview of the possibilities for the application of new methodol-
ogies to food ingredients and the mixtures in which these are
present in food matrices. The need for new strategies is also driven
by the desire to develop more relevant models with respect to a
better predictability for the human situation, as well as by the
increasing number of compounds and mixtures thereof for which
safety assessments are required. The challenge will be to apply
these approaches to the safety assessment of foods and food in-
gredients, given their inherent complexity.
It is important to recognise the safety of foods and food in-
gredients, novel or already in use, is not solely based on toxico-
logical considerations. The nutritional properties and other
beneﬁcial characteristics must also be taken into consideration.
This paper will present an overview of:
- the availability and applicability of methodologies for the safety
assessment of (novel) foods, food ingredients and mixtures;
- the construction of a roadmap that can be applied to determine
safe levels of exposure;
- the gaps in our knowledge and in the availability of the
methodologies.
Furthermore, recommendations will be formulated for research
needs in this area. In line with the recommendations in the NRC
2007 report (NRC, 2007), it is important to mention the possibil-
ity of creating strategies that are best suited to focus on the human
risk assessment by implementing toxicity testing systems, e.g.
derived from human tissues, and applying kinetic and dynamic
modelling techniques speciﬁc for the human situation.
It is clear that there will not be a “one size ﬁts all” strategy; the
applicability for a number of roadmaps are described. The robust-
ness and reliability of a number of chosen strategies will then be
illustrated using a number of case studies. The roadmaps should be
as small as possible and no larger than necessary, also taking ac-
count of the cost-effectiveness and practical applicability in food
safety.
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toxicological risk assessment paradigms
This paper reviews the possibilities and opportunities of
implementing the recently developed concepts and methods for
toxicity testing for the safety evaluation of food and food in-
gredients and thereby avoiding animal experimentation if possible.
It extends the work in the ILSI-Europe FOSIE project (Smith, 2002;
Eisenbrand et al., 2002). Since the publication of the NRC report
“Toxicity testing in the 21st century, a vision and a strategy” (NRC,
2007), a range of activities has been started to interrogate the
possibilities of integrating elements of the changes in the way
toxicity (or safety) testing could be performed, as proposed in this
seminal report. The views presented in that report can be consid-
ered a true paradigm shift for the science of toxicology and for
safety assessments.
The main emphasis in this new vision is on the shift from using
clinically and/or histopathologically observable apical endpoints
for adverse effects of a substance in models consisting of intact
animals, towards a more detailed description of the process of
adversity that makes use of the mechanism of action at the mo-
lecular level. This runs in parallel with the opportunities provided
by technological innovations (Leist et al., 2012) and the imple-
mentation of new scientiﬁc concepts with regard to new in vitro
and in silico approaches, as well as concepts from the ﬁeld of sys-
tems biology. The integration of the derived toxicity data into a
systems biology-type description (Hartung et al., 2012), referred to
as modes of action or adverse outcome pathways, together with
computer-based kinetic modelling might then result in a risk or
safety assessment and at the same time reducing the number of
animal studies needed. When human-based cell or tissue cultures,
or even human data, can be employed, a more direct relevance to
the human situation can be obtained. This will allow a “ﬁt-for-
purpose” approach that can be ﬂexibly adapted to the questions to
be answered in safety assessments. Well-described problem for-
mulations are the basis for testing strategies that should offer
sufﬁcient precision to solve the problem while, at the same time,
avoid unnecessary testing.
The new paradigm opens up the opportunity for integral
assessment and evaluation of risks related to mixtures of com-
pounds to which individuals are exposed, i.e. description of expo-
some and the human toxome (Rappaport, 2011; Hartung and
McBride, 2011). In this regard, scientiﬁc challenges lie in under-
standing the mechanisms underlying biological responses, in
evaluation and extrapolation of data derived from pathway-based
approaches, and in interpretation of complex toxicological end-
points for decision ﬁnding processes.
There is evidence from mechanistic toxicology studies aimed at
Modes of Action (MoA) of compounds suggesting that the thou-
sands of known harmful substances act by interfering with only a
few cellular key molecular pathways (NRC, 2007). Information on
involved pathways can be obtained by high-throughput and high-
content screening systems, e.g. omics (Heijne et al., 2005) and
modern imaging approaches, using human cells and organotypic
tissue cultures. This information can be further analysed with
modern methods of systems biology and bioinformatics. Imple-
mentation of this vision proposed by the NRC report (NRC, 2007) is
needed and has been started via regulatory authorities such as
OECD and US-FDA (Collins et al., 2008; Schiffelers MJ et al., 2012).
This concept also includes the concept that the knowledge of
(quantitative) structure-activity relationships ((Q)SAR) of exposure
and the knowledge of MoA of toxicants on these pathways allow
predictions of toxicity at the level of the whole organism. The
conceptual construct concerning the linkage between direct mo-
lecular initiating events and an adverse outcome at a biologicallevel is also referred to as an adverse outcome pathway (AOP)
(Ankley et al., 2010). Currently, several AOPs are under develop-
ment under the management of OECD Extended Advisory Group on
Molecular Screening and Toxicogenomics. With reference to the
new concepts in toxicology, the safety evaluation of compounds is
to begin with chemical properties and then proceed to the bio-
logical characterisation in multiple in vitro systems, i.e. test batte-
ries. These functional assays address MoA of compounds result in
information relevant to human physiology, which should be
translated to hazard estimates (Blaauboer BJ et al., 2012).
Ideally, toxicological risk assessment should be based on the
integration of the computational approach and the experimental
proﬁling approach (Blaauboer, 2010). Data from experimental
proﬁling reﬁne the in silico approaches and results of computa-
tional approaches narrow the subset of test substances and provide
matrices for interpretation and interpolation of the experimental
proﬁling data. Examples of computational approaches and in silico
predictive models are QSAR (Benfenati, 2013) and physiologically-
based biokinetics models (PBBK) as well as (quantitative) in vitro-
in vivo extrapolation ((Q)IVIVE) approaches (Polak, 2013). The QSAR
approaches correlate descriptors of chemical characteristics of
compounds with their biological activity. PBBK involves various
mathematical models for description of adsorption, distribution,
metabolism and excretion (ADME) of compounds within an or-
ganism on the basis of physiological (e.g. body ﬂuid ﬂows), physico-
chemical (e.g. partition coefﬁcients) and kinetic (e.g. metabolic
rates) parameters. The PBBK provides a framework for conducting
QIVIVE, as the prediction of biological activity of compounds im-
plies the integration of data on the MoA with data on biokinetics
(DeJongh et al., 1999; Blaauboer et al., 1999, 2000; Blaauboer, 2001,
2002; 2003; Verwei et al., 2006; Louisse et al., 2010). QIVIVE esti-
mates the effect of compounds on tissues and on the whole or-
ganism, based on their effects in an in vitro toxicity test system at a
certain exposure level (Yoon et al. 2012). The computational ap-
proaches depend on available existing data with regard to various
endpoints and thus on the quality and extent of databases, which
grow continuously due to the data from proﬁling approaches as
well as due to epidemiological data.
This paper describes the more speciﬁc aspects of the safety
assessment of food and food ingredients, also paying attention to
the development of novel foods and the complexity of food
composition and thus the complexity of safety testing in this area.
This is followed by the description of a number of new de-
velopments and methodologies that have the potential to be
applied in future food safety testing. A strategy is being proposed in
which elements of the new developments could be implemented in
a stepwise integrated roadmap for a practical use in food safety
assessment in the near future. By describing some historical cases
the usefulness of the suggested approach is demonstrated.
4. Considerations for the development of a roadmap for a
future integrated strategy for safety assessment of foods and
food ingredients
Today, the acceleration in knowledge generation, science pro-
gression and development of innovative technologies, open up the
opportunity for combining new concepts in safety sciences and
corresponding new technologies with good laboratory practices
(van Thriel et al., 2012). New toxicological risk assessment strate-
gies ﬁnally aim at in silico evaluation and literature/database
search, to make use of existing and human/epidemiological data,
and in parallel at in vitro based human-relevant hazard assessment
and appropriate exposure assessment.
Also in the ﬁeld of risk assessment of food and food ingredients
it is very difﬁcult to aim for one-to-one replacement of a traditional
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on the knowledge and understanding of the mechanisms under-
lying an adverse effect. For more complex endpoints several non-
animal approaches may be required for characterisation of the
impact of a compound on the relevant tissues. Examples are car-
cinogenicity or sensitisation.
For evaluation of the toxicological capacities and for nutritional
assessment it is necessary to start with an exposure assessment.
Exposure assessment is deﬁned as the process for estimation and
measuring the magnitude, frequency and duration of exposure to a
compound, along with the number and characteristics of the pop-
ulation exposed, including the pathways, the routes, and also the
uncertainties (Lioy, 2010). In the case of food and food ingredients,
the exposure situation is to be considered as long-term repeated-
dose exposure with the potential for systemic effects. This has
consequences for selection criteria involved in choosing in vitro
methods with regard to their signiﬁcance and to the time frame
within which they are able to deliver sensitive, robust and repro-
ducible results. As the animal models do not always mirror human
physiology adequately (Leist and Hartung, 2013) and as there are
currently no in vitro approaches available to test compounds over a
very long period, it stands to reason that in this ﬁeld the efforts for
risk assessment have to parallel the compilation of data from
epidemiological and human studies. These data have the potential
to improve the human risk assessment signiﬁcantly, as they would
provide information on long term effects, enable retrospective
evaluation of results from in vitromethods, and lead to knowledge
about effects on frequently affected populations and about differ-
ences in repeated response due to variations between populations.
Where there is a lack of relevant safety data on foods and food
ingredients for the establishment of an adequate risk assessment in
this ﬁeld, innovative technologies and molecular techniques are
investigated on how and if they can provide integral, human-
relevant and reliable information. The roadmap for implementa-
tion of the new toxicological approaches in this ﬁeld provides op-
portunity for elucidation of mechanisms/modes of action, inclusion
of intraspecies and interspecies variabilities, correlation of animal
data with in vitro data and epidemiological data (human studies
and patients data), development of foods and food ingredients on
the basis of new scientiﬁc ﬁndings, and the development of valid
approaches (Hartung et al., 2013a) for integration of large datasets.
Current new approaches would allow addressing relevant
organ-speciﬁc features, such as absorption and metabolism
(Ramirez et al., 2013) by recruiting test systems mimicking human
organs and involving new ﬁndings on the gene, protein and
metabolite level. The intestinal system and the liver can be
mimicked by 2D and 3D cell culture systems in bioreactors, and for
these systems organotypic tissues and functional units, e.g. intes-
tinal villus, are already available. Also ex vivo viable human tissue
can be used for screening purposes. Communicatingmicro-reactors
and organs-on-chip approaches would also allow investigating the
inﬂuence of distinct organs on each other, i.e. intestine, liver, adi-
pocytes. New bio-barrier systems for intestine, placenta and brain
allow the investigation of transport phenomena, as well as the
inﬂuence on the coherence of these barriers. The choice of the
adequate system depends on signiﬁcance, sensitivity, robustness
and scientiﬁc validity of the system, but with the variety of prom-
ising approaches and technologies available this choice may also
depend on demands of the experimenter and risk assessor.
With regard to large datasets to be expected from high-content,
high-throughput proﬁling approaches (-omics) and testing batte-
ries, there is a need for development of tools for extraction and
weighing of relevant information (Judson et al., 2013), especially in
cases in which low probability events are in the centre of focus,
which are in contrast to deterministic methods, which have thefocus on worst-case estimates. As modern toxicological risk
assessment approaches result in multiple pieces of evidence, the
main conceptual requirements for a multi-test decision framework
are a probabilistic strategy (addressing uncertainties and de-
pendencies): a consistent feature in allowing reasoning in both
causal and predictive directions and supportive with regard to
hypothesis and data-driven approaches, where the hypotheses can
be updated when new data are provided. The approach of proba-
bilistic risk assessment with integrated testing strategies (Stefanini,
2013; Hartung et al., 2013b) is to be an essential part of the new
toxicological risk assessment approach and is to be integrated in
the roadmap for new risk assessment strategies of foods and food
ingredients.
In conclusion, any strategy for evaluating the safety of food and
food ingredients should be able to address at least the following
items:
 Chemical identity/structural activity relationships
 Relevant exposure scenarios
 Digestibility/stability
 Absorption and distribution (internal exposure)
 Metabolism
 Genetic toxicity and Carcinogenicity
 Repeated dosing
 Tolerance/allergenicity
 Other systemic endpoints case by case (e.g. reproductive and
developmental toxicity)
 Target population speciﬁc testing (e.g. term infants and preg-
nant women)
In the following chapter a few new technologies will be
described that could ﬁt into the above mentioned items.
5. Useful testing methods to be applied in food safety
strategies
The number of newly developed methods to determine the
adverse effects of substances in sophisticated in vitro and in silico
systems is overwhelming. This manuscript focuses on a number of
thesemethodologies that may be advantageous when incorporated
in integrated strategies for toxicity testing in the area of food safety.
This overview is therefore by no means meant to be exhaustive and
can be supplemented with many other examples.
The choice of the adequate non-animal assays, e.g. in vitro cell
culture, depends on the question the system is able to address.
Ideally, the systems mirror the features and responsiveness of hu-
man tissue. A functional and physiological test or test battery
mimics the regular amplitude of organ response and variations as
well as the reactivity on gene, protein and metabolite level in a
concentration-response manner. Furthermore, these systems need
to be sensitive, robust and reliable, and they should deliver repro-
ducible and quantiﬁed data. In addition, the biological non-animal
methods should preferably be able to be downscaled and auto-
mated to enable higher throughput (Wang et al., 2013). Moreover,
the biological material, e.g. cells, should be easily accessible also in
high quantities and their implementation and use should be
possible without rigorous efforts.
For the study of many toxicologically relevant endpoints speciﬁc
cell culture systems are available (Adler et al., 2011; Basketter et al.,
2012). Distinction needs to bemade between the study of a-speciﬁc
or basal cytotoxicity (i.e. the effect on any cell type, mainly due to
membrane damage, disturbance of energy supply, cell compart-
mentalisation) and more speciﬁc functional cell function distur-
bances, that can be related to a particular target cell, tissue or organ.
For studying the latter form of toxicity, the knowledge of an AOP for
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5.1. (Stem) cell cultures to study absorption and systemic toxicity
In many cases the use of primary cell cultures are considered the
“golden standard”, being a better representation of normal in vivo
physiology than cell lines. However, in general, human primary
cells are not readily available. Moreover, primary cultures have the
tendency to lose their organ-speciﬁc differentiation characteristics
over time. The majority of cell culture systems now in use are
therefore cell lines, preferably of human origin, and the limitations
of these cell lines should be taken into account.
There is an increasing number of in vitro systems based on stem
cell technologies. Stem cells are capable of dividing indeﬁnitely and
have the potential to differentiate into any cell type. Induced
Pluripotent Stem Cells (iPSC) derived from adult, differentiated
cells, are to regain pluripotency and thus may provide even better
in vitro models to include in toxicology assessments. Since stem
cell-derived in vitro systems can be stably maintained over pro-
longed periods of time in culture, these systems can be used in
repeated dose toxicity studies in vitro (Suter-Dick et al., 2015). The
application of stem cells in the production of organoids, that better
mimic in vivo structures is yet another interesting area that may be
applicable in studying organ-speciﬁc (systemic) toxicity (Foster
et al., 2014).
Stem cell lines are in use for a long time as models for embry-
otoxicity, avoiding the use of animal embryos, i.e. by recruiting
mouse embryonic stem cell lines (mES) (Scholz et al., 1999;
Rolletscheck et al., 2005). Human embryonic stem cells (hESC)
are also more and more involved in toxicology and biomedical
research (Thomson et al., 1998). The EC funded project “Vitro-
cellomics” established an in vitro hepatotoxicity assays based on
hepatic cells derived from hESC, including screening assays
combining the hepatic model system with micro-sensor platforms
for measuring absorption, cytotoxicity and metabolism (Beckers
et al., 2010).
iPSC driven from somatic cells show features of hESC (Takahashi
et al., 2007; Yu et al., 2007) and are accepted as an innovative
technology, and already recruited in toxicological experiments. As
the iPSC generation requires genetic modiﬁcation of the cell nuclei,
this approach leads to establishment of genotype-speciﬁed cell
lines with the characteristics of hESC.
5.2. 3D cell culture models and organotypic tissues for metabolism
In vitro human 3D organotypic models have signiﬁcant advances
compared to monolayer cell culture models (Alepee et al., 2014).
For risk assessment, these models provide important features as
there are normal human cells (non-tumor cells), they have orga-
notypic structures, they mimic the barrier functions, they open
realistic exposure options, and as they show physiological meta-
bolism features (Kandarova et al., 2009; Kaluzhny et al., 2011).
A challenge to the ﬁeld of tissue engineering pose the gastro-
intestinal tract, as the intestinal epithelium is a complex, rapidly
renewing tissue with a distinct functional architecture. The ap-
proaches for engineering the gastrointestinal tract relevant to
toxicity testing are based on organoids. These organoids are ob-
tained by section of intestinal tissue, which is then seeded to a
scaffold made of biodegradable materials. Such approaches have
already been published on tissues from oesophagus, small bowel,
colon and stomach (Fuchs et al., 2001; Sato et al., 1997; Choi et al.,
1998; Grikscheit et al., 2003; Hori et al., 2001).
A novel approach for establishment of crosstalk between
different cell cultures -also in 3D-aiming at overcoming the difﬁ-
culty of translation of milliscale to microscale (e.g. with organ-on-chip approaches), is the modular multi-compartmental bioreactor
array, the quasi vivo approach. The quasi vivo approach enables the
transfer of microwell protocols directly to the bioreactor modules,
offering mechanical stimuli from ﬂow and biochemical stimuli
from cells placed in connected modules (Mazzei et al., 2010).
Another major challenges is engineering an organ, e.g. the liver,
as the in vitro models do not show the regenerative features, they
show loss of functionality beginning after 24 h and as there are
rapid changes in gene expression in vitro. As liver is a complex
tissue, the different cell types have to be combined for establish-
ment of an in vitromodel, and also a rigorous perfusion system has
to be integrated. Here new bioreactor technologies may open up to
new possibilities, as these can include better oxygenation, e.g. by
introducing gas-permeable ﬁbers into the 3D tissue. This innova-
tive approach resulted in higher metabolic activity, promotion of
different cell types to liver-organotypic organisation, to signiﬁcant
elongation of functionality (20 days) and also spontaneous devel-
opment of bile canaliculi and sinusoid-like structures (Gerlach
et al., 1990; Zeilinger et al., 2002, 2004). Microarray bioreactors
involving spheroids with integrated ﬂuid ﬂow could already show
to be able to mimic the liver blood ﬂow dynamics (Powers et al.,
2002). In addition, in co-culture of hepatocytes and non-
parenchymal cells (in a ﬂat-bed bioreactor with controlled oxy-
gen gradients) hepatic zonal patterns (region speciﬁc zonation)
could be established, which were comparable with the zonal pat-
terns in vivo (Allen et al., 2005).
5.3. Organs-on-chips
For mimicking the human physiology with in vitromethods it is
inevitable to involve more cell types. With the complexity the
likelihood of unpredictability and variations increases. The organ-
on-chip approaches are micro-engineered microﬂuidic models
including physiological micro-environment parameters, e.g.
geometrical, mechanical and biochemical factors, for in vitro mea-
surement, and are prone to be accessible as high throughput
approaches.
As the organ-on-chip technology is based onmodulation of ﬂuid
ﬂow (microﬂuidic), it stand to reason that the vascular system and
the endothelial response (e.g. to shear stress) can be addressed
easily by this technology (van der Meer et al., 2009). Besides the
readily accessible shear stress studies on endothelia in blood
vessel-on-chip approaches also other features, e.g. cholesterol up-
take and cytokine-induced direction on leukocytes could already be
studied with this approach (Song et al., 2005; Shin et al., 2004; van
der Meer et al., 2010; Srigunapalan et al., 2011).
The gut-on-chip approach is construct that is to mimic the ge-
ometry of intestinal villi as a more physiological and functional
in vitro model of the intestine (Sung et al., 2011). The Nutrichip
poses a microﬂuidic system for in vitro investigation of the
immunomodulatory function of food ingredients. This approach
involves Caco-2 cells (Ferruzza et al., 2013) in co-culture with THP1
cells aiming to address immune cell biomarkers (Ramadan et al.,
2013).
There are numerous records of liver-on-chip approaches for
screening purposes and for addressing the liver function (Baudoin
et al. 2007; van Midwoud, 2011). It could also be shown, that the
culturing of primary hepatocytes (clusters) on micro-patterned
spots surrounded by ﬁbroblasts will lead to preservation of he-
patic functions for a signiﬁcant longer period (Khetani and Bhatia,
2008).
The kidney-on-chip approaches could show, that cultured renal
epithelial cells exposed to physiological levels of ﬂuid ﬂow and to a
two-compartment microenvironment form differentiated and
functional monolayers with apical-basolateral polarity (Ferrell
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There are various successful attempts to establish a pancreas-
on-chip system, involving pancreatic islets of Langerhans. This
approaches aim at examination of hormone kinetics (Wang et al.,
2010).
The brain-on-chip approaches have also been shown to be
relevant in constructing neuronal models as the outgrowth can be
directed in two or three dimensions by generating surface-bound
or soluble biochemical gradients, and as this directed outgrowth
can be combined with electrical activity, physiologically relevant
measurements can be made (Wang et al., 2009).
The heart-on-chip approach aims at examination of mechanical
(shear stress, stretch and relaxation) and electrical stimulation of
matured and differentiating cardiomyocytes, revealing clear ad-
vantages of the microengineered system (Ghafar-Zadeh et al.,
2011).
5.4. Models to investigate digestion and bioaccessibility
In contrast, macro systems mimicking the gastrointestinal tract
are also successfully established and validated for assessment of
nutritional and functional properties of foods and ingredients un-
der simulated physiological digestion conditions, i.e. TIM-1 and
TIM-2. These systems are multi-compartmental, dynamic
computer-controlled models, whereas TIM-1 simulates the diges-
tive processes of stomach and small intestines and TIM-2 repre-
sents the colon and includes a rich microbial gut-derived ﬂora
(Havenaar, 2011).
Another promising approach for analysis of gastrointestinal
tract is the approach of immobilised digestive enzymes in micro-
ﬂuidic process reactors, which can give insight in which metabo-
lites and intermediates are present during the digestion also by
subsequent proteome analysis (Asanomi et al., 2011).
5.5. Biokinetics (ADME)
For the evaluation of a compound's toxicity it is essential to
obtain knowledge on its biokinetic behaviour. An analysis of the
absorption, distribution and metabolic or renal clearance provides
insights in the exposure of possible toxicological targets in vivo. For
estimating absorption via the oral route a number of well-
established in silico and in vitro methods are available. However,
although these methods are in use in the area of pharmaceutics,
only limited information is available for other areas, including food
ingredients and matrices. For estimates of ADME behaviour the use
of physiologically-based biokinetic (PBBK) models are very helpful
and in use in many areas, and since these methods can be to a great
extend based on non-animal methods (Bouvier D'Ivoire et al. 2007;
Bessems et al., 2014), this will be an important element of novel test
strategies.
Apart from being relevant for the toxicodynamic characterisa-
tion of a compound, the use of in vitro systems also need to be
relevant with regard to the cellular exposure to the compound. First
of all, this implies a good characterisation of the biokinetics in the
in vitro systems themselves (Kramer et al., 2015). This includes also
the information on the intracellular concentrations, on the con-
centrations in different cellular compartments as well as on the
extracellular concentrations To perform an in vitro to in vivo
extrapolation (IVIVE), the real concentration of a compound has to
be determined (Coecke et al., 2012: Groothuis et al., 2015), as the
free concentration of a compound is not necessarily identical to the
nominal concentration; compounds may bind to the device mate-
rial or to biomolecules or they may evaporate or be metabolised
quickly (Kramer et al., 2012).
The other element of the biokinetic considerations in a safetyassessment based on in vitro methods is the in vitro-in vivo
extrapolation of the data. This implies the translation of the effec-
tive concentrations in the in vitro systems to an exposure scenario
in vivo, making use of reverse dosimetry (Yoon et al., 2012;
Blaauboer et al., 2012). The tool to apply is physiologically-based
biokinetic modelling. PBBK models describing the kinetics are be-
ing made for individual compounds, which hampers the applica-
tion in risk assessment. However, generic PBBK models are under
development which will largely decrease resources (time and
costs) and accelerate implementation (Bessems et al., 2014). PBBK
should be extended for evaluation of biodynamic processes and
also extended for involvement of a higher number of compounds.
This methodology should be also modiﬁed to allow combination of
in vitro toxicity and ADME data with in vivo dose-response curves.
QSAR, PBBK, IVIVE are often used as stand-alone approaches, but
the integration of these approaches may lead to testing strategies
that result in replacement or reduction of animal tests.
5.6. Biotransformation
Since a compound's toxicity is highly determined by its meta-
bolism, either by minimising the toxicity through detoxifying re-
actions or by enhancing toxicity (bioactivation), the relevance of
using in vitro systems to predict toxicity is depending on the
presence (qualitatively as well as quantitatively) of biotransfor-
mation reactions in these systems. In many existing in vitro systems
biotransformation is not an appropriate mirror of the in vivo situ-
ation (Coecke et al., 2006). Therefore, results of in vitro experiments
need to be interpreted with care, especially when a compound's
metabolism is located in one organ (e.g. the liver) while the toxicity
(of the metabolite) is expressed in another tissue or organ.
The use of appropriate in vitro systems (Rossini and Hartung,
2012) allows the quantiﬁcation of the relevant biotransformation
reactions and systems have been described to scale the outcomes
up to the formation of metabolites for the in vivo situation (Yoon
et al., 2012, 2014).
5.7. QSARs
In silico modelling is already a prerequisite in many areas of the
risk assessment ﬁeld (Hartung and Hoffmann, 2009; Raunio, 2011)
and is to be also an integral part of toxicological assessment of foods
and food ingredients. Non-testing data can be generated by several
approaches, including grouping approaches, which consist of read-
across and chemical category formation, structureeactivity rela-
tionship (SAR) and quantitative SAR (QSAR). A structural physico-
chemical reactivity characterisation of compounds is currently
done routinely (Valerio, 2009, 2011). Further, provided that the
subset of nutritional compounds shares structural similarity with
chemicals or drugs this approach may be able to use the larger
amount of SAR and QSAR approaches available from pharmaceu-
ticals and industrial chemicals.
For the QSAR approach there is a need for development of
methods to assess mixture effects, and also for development of
intuitive software or artiﬁcial intelligence matrices for more
comprehensive use of databases. QSAR also needs possibilities for
software matrices for more sensitive and selective prediction
models.
5.8. The usefulness of the above-mentioned technologies for the
safety evaluation of food and food ingredients
In chapter 4 the essential elements for these safety assessments
are listed. For some of these elements the necessary data can be
acquired by methods that are outside the realm of testing, e.g. for
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identity of compounds and the composition of more complex food
and food matrices. Stability and digestibility are elements that may
require chemical and biochemical test methods.
For a determination of absorption, which parameter is deter-
mining the internal exposure to compounds, progress has been
made to determine this in in silico (QSAR) and in vitro systems. The
same applies for estimating biotransformation; the formation of
metabolites can be determined in in vitro systems and parameters
such as intrinsic clearance can be scaled up, e.g. to serve as input
parameters for PBBK modelling. A drawback of these methods is
that analytical tools are needed to quantify metabolite formation,
thus hampering the incorporation in high-throughput systems.
The use of in vitro evaluation of genotoxicity has been performed
over a long period. The increasing knowledge of the mechanisms
involved in the effects on the genome and its relation to carcino-
genic endpoints also opens possibilities to include this in an eval-
uation scheme less relying on animal studies.
The ever increasing number of test systems focussing on the
mechanism of toxicity with speciﬁc target tissues and organs is
now even faster progressing. Depending on the issue at stake, cell
culture systems consisting of 2D, single cell cultures might answer
the more basal questions, while the application of 3D cultures
(spheroids), stem cell-derived cultures etc. would be more appli-
cable for speciﬁc toxicity. For the future, organ-on-chip models or
bioreactor-type approaches are promising tools. The more sys-
tematic way in which modes of action, e.g. by describing adverse
outcome pathways, is also opening possibilities to better include
in vitro toxicity data in risk evaluations. And although in the past
the focus has been on short-term effects that were most of the time
related to acute toxicity, a number of studies have been done in
which prolonged or repeated exposure were evaluated with in vitro
methods (e.g. the Predict-iv project, Wilmes et al., 2013).
The more speciﬁc endpoints such as tolerance, allergenicity,
reproductive and developmental toxicity have been studied in
in vitro systems, however, work needs to be done to evaluate these
methods for the area of food and food ingredients.Fig. 1. Evaluation roadmap for safety assessment of food and ingredients. Numbers represen
text). The information provided by the blocks with green arrows is related to exposure. The
routes and may provide additional information to (re)consider the next steps.Many of the results of these mechanistic studies based on
in vitromethods will have to be evaluated for their relevance in an
intact (human) organism. These in vitro-in vivo evaluations will
have to be quantiﬁed (QIVIVE) to be useful in a risk or safety
evaluation.
If speciﬁc target populations are the issue, the parametrisation
of the QIVIVE process should be tailor-made for such situations,
including a probabilistic rather than a point-estimate approach.
For all the above-mentioned methods and technologies it
should be kept in mind that these will need to cover the range of
less or more complex situations often observed in the food area,
ranging from individual compounds and enzymes to increasingly
complex mixtures.
6. An evaluation roadmap
Based on the above considerations a roadmap for safety
assessment of food and ingredients (Fig. 1) was developed. The
roadmap consists of a number of blocks that describe activities or
decision steps to be taken. Each block activity aims at answering
speciﬁc questions that then may lead to activities in the following
block. It is also possible that iterations to earlier blocks in the
roadmap are necessary. The speciﬁc aspects of each block are
further described in the explanatory text.
Explanations of steps, routing and considerations for Fig. 1.
1) Deﬁne the type of food: is it a chemically deﬁned ingredient? a
complex food ingredient? a non-nutritional compound? what is
intended target population and use? This information helps to
deﬁne what kind of data should be collected.
2) Provide information on: physico-chemical properties (incl. sol-
ubility) and characterisation of the material (material speciﬁ-
cation): identiﬁcation of (non) nutritional compounds: changes
in composition due to production process (impurities).
3) Apply computational approaches to predict e.g.:
- QSAR/QSPR (impurities);
- Bioaccessibility and bioavailability (behaviour in GI tract);t the ﬂow and the solid blocks with blue arrows the main stream (methods explained in
dotted blocks are ‘outcomes’ of the previous blocks and the dotted lines are feedback
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- Virtual tissue/organ models for safety/efﬁcacy assessment.
4) Exposure assessment: estimation of daily exposure and apply
TTC concept in case of non-nutritive compounds or impurities.
Consideration: if in silico predictions lead to one or more alerts
(thus not only ‘approved’ alerts such as genotoxicity) and/or the
exposure is estimated to exceed the threshold of toxicological
concern, which is often the case for foods and food ingredients,
further testing is needed.
5) Design an integrated testing strategy with appropriate assays
(choices should be based on the alerts, but also including con-
siderations regarding a speciﬁc target population (pregnant
women, infants)) that can identify mode of action(s), determine
dose response relations and measure parameters/read-outs that
are translational to human population.
6) Perform in vitro assays (consider both nominal and measured
dose concentrations), preferably medium/high throughput and
based on human cells or tissues. Make use of new technologies,
such as omics, imaging, etc. and include biokinetic data.
7) Apply bioinformatics tools and systems biology to integrate data
and identify signatures (ﬁnger prints) and mode of actions.
Consideration: can activated pathways be identiﬁed?Whenwill
they become adverse? If so, what will be the point of departure for
the in vitro-in vivo extrapolation and the ﬁnal safety assessment?
8) Data obtained from the in vitro assays should be collected and
stored in databases, in such a way that the current in silico tools
can be improved and/or new QSAR models can be build.
9) In cases where in vitro assays do not lead to conclusive results or
do not address the relevant endpoint, or approval is needed
in vivo, animal studies might be more considered. These tests
should be designed using information from the other ap-
proaches, such as mechanistic data (e.g. from omics analyses)
and can be directly used for quantitative risk assessment. These
data should also be included in the databases to ‘validate’ the
in vitro assays.
10) Measure the real exposure and ADME (human data), specif-
ically for target groups such as children, elderly and obese
population.
11) Combine exposure data and in vitro data to extrapolate from
in vitro to in vivo, by using PBPK modelling, assessing how well
the in vitro system mimics in vivo and considering any
uncertainties.
12) Perform risk assessment, determine safety levels and human
ADI or reference daily intake (RDI) for general public and target
groups
13) Rational and mode of action supporting the beneﬁcial or
technological effects of the food or food ingredient should be
considered as part of the effect spectrum, to be able to inter-
pret potential adverse effects related to the same mode of
action. This information also serves to make a risk beneﬁt
assessment
Consideration: What is the margin of safety? Is information on
nutritional (beneﬁcial) effect present? If so, is it achievable toweigh
risk and beneﬁt, taking into account target populations, severity of
the effect (deﬁciency versus toxicity)?7. Case studies
Cases are selected on foods and food ingredients for which
safety assessment are available by EFSA, JECFA, making use of an-
imal and human data. Taking these cases through the decision tree,
while making use of new available methods may demonstrate in
what way new methodologies could improve food safety
assessment.
Cases should have at least the following elements:
1) A well-deﬁned question regarding the safety of a food ingre-
dient or product.
2) The collection of information, where possible, on the structural
physico-chemical properties, matrix, mixture etc.
3) Collection of information on possible exposure scenarios for
consumers (e.g. possibility of application of TTC).
4) Based on this information: leads for selection of possible MoA
for toxic effects, target tissues and endpoints (qualitative info).
5) Selection of appropriate in vitro and in silicomethods to evaluate
these MoA/endpoints: are these available, are these evaluated?
6) Integrate knowledge on possible toxicity with knowledge on
kinetics (e.g. bioavailability after oral (human) consumption,
distribution, metabolism, clearance), data preferably derived
from in vitro or in silico data.
7) Extrapolate data to a human exposure scenario: reverse
dosimetry, quantitative in vitro-in vivo extrapolation.8. Selected cases
In the next paragraphs a number of foods and food ingredients
following the roadmap in Fig. 1 were evaluated. The product
speciﬁcation or manufacturing processes involved as well as the
history of use or the intended use of the products inwhich the food
was or would be present was taken into account, assuming there
was no existing safety data knowledge based on animal studies.
8.1. Case 1: steviol glycosides
Box 1. Intended Use; Food Application; Use levels; Target
population.
Stevia rebaudiana is a plant native to South America and has
been used to sweeten beverages and food for several centuries. The
plant has also been distributed to Southeast Asia. Steviol glycosides,
the principle sweetening components are low-calorie, high-in-
tensity sweeteners (~200e300 times sweeter than sucrose) of
similar taste quality as sucrose, which provide an alternative to the
already approved high-intensity sweeteners and are stable to heat.
The uses and use levels for steviol glycosides intended to be used in
food categories, targeting the general population, reﬂect those
currently permitted for aspartame in the EU with some major
exceptions.
Box 2. Physical-chemical characterisation.
The manufacturing process comprises two main phases: the
ﬁrst involving water extraction of the leaves of the S. rebaudiana
Bertoni plant and preliminary puriﬁcation of the extract by
employing ion exchange chromatography to yield a steviol glyco-
side primary extract, and the second involving recrystallisation of
the steviol glycosides from methanol or aqueous ethanol resulting
in a ﬁnal product.
The steviol glycosides produced are chemically deﬁned
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rebaudioside A. Stevioside and/or rebaudioside A are more than
95% of the mixture in some of the available products. In another
product, rebaudioside A is the major component of the mixture
(95%) together with other glycosides. In addition, smaller
amounts of rebaudiosides B, C, D, E and F, steviolbioside, rubusoside
and dulcoside A are present in the compositions of ﬁnal mixtures.
The mixtures are described as white to light yellow powders,
odourless or having a slight characteristic odour, about 200e300
times sweeter than sucrose, freely soluble in water and a pH be-
tween 4.5 and 7.0 (1 in 100 solution).
The JECFA speciﬁcations outlines that the purity of steviol gly-
cosides should not be less than 95% of the total amount of the seven
named glycosides (stevioside, rebaudioside A, rebaudioside C,
dulcoside A, ubusoside, steviolbioside and rebaudioside B) on the
dried basis with the major glycosides in the product being stevio-
side and rebaudioside A. In the EU speciﬁcations it was proposed to
also include rebaudioside D and rebaudioside F, two minor steviol
glycosides, which may also be present in the ﬁnal mixture.
According to JECFA (2007), impurities occurring in extracts of
Stevia leaves are typical plant materials, such as pigments and
saccharides. One literature study reports identiﬁcation of the
following substances in the non-glycosidic fractions of extracts of
Stevia leaves, obtained using Supercritical Carbon-dioxide Fluide
Extraction (SCFE): spathulenol; decanoic acid; 8,11,14-ecosatrienoic
acid; 2-methyloctadecane; pentacosane; octacosane; stigmasterol;
b-sitosterol; a- and b-amyrine; lupeol; b-amyrin acetate; and
pentacyclic triterpene. These substances (corresponding to
approximately 5% of the steviol glycosides preparation) represent
56% of the total non-glycosidic extracts, while 44% remain un-
identiﬁed. The speciﬁed additive (>95% total steviol glycosides) will
contain, in addition to saccharides other than those associated with
the individual steviol glycosides, residual extraction/recrystallisa-
tion solvent and possibly also residues of ion-exchange resins used
in the manufacturing process.
According to JECFA, the level of the non-glycosidic fraction,
because of its highly non-polar character, can be considered
insigniﬁcant in the additive.
Several other related steviol glycosides that may be generated as
a result of the production process but do not occur naturally in the
leaves of S. rebaudiana plant, have been identiﬁed in small amounts
(0.10e0.37%, w/w) by High Performance Liquid Chromatography
(HPLC) in the steviol glycoside bulk material. Some of them share
the same steviol aglycone backbone structure as rebaudioside A
and differ only with respect to the number of glucose units, while
the remaining compounds have slight structural differences in the
aglycone backbone like an endocyclic double bond, an additional
hydroxyl group or isosteviol instead of steviol aglycone.
Box 3. Information on GIT metabolism/bioavailability.
In vitro assays with human/animal enzymes: These experiments
have been conducted and could well be used following the roadmap:
Stevioside metabolism was studied by adding various digestive
enzymes or ﬂuids like salivary a-amylase, pancreatic a-amylase,
saliva, pepsin, gastric secretion, pancreatin and intestinal brush
border membrane enzymes of rodents as well as by the intestinal
microﬂora of various species including humans (Hutapea et al.,
1997). None of these enzymes digested stevioside. However, the
caecal microﬂora of all species tested was able to metabolise ste-
vioside to steviol the aglycone. A transient formation of steviol-16,
17 a-epoxide was observed in mouse caecal contents and human
feces. It was suggested that steviol is the major metabolite pro-
duced by caecal microﬂora from various animal species and
humans. The Stevia mixture, stevioside and rebaudioside Aappeared also to be hydrolysed to the aglycone steviol by human
intestinal microﬂora after incubation with human intestinal
microﬂora (faeces).
Intestinal transport of steviol was studied in Caco-2 cells: steviol
permeability was 200e300 times higher compared to stevioside or
rebaudioside, indicating poor oral bioavailability of the glycosides.
The hepatic metabolism was studied of steviol, by using human
liver microsomes versus rat to include also species difference:
steviol undergoes glucuronidation and low conversion into oxida-
tive metabolites, no major difference in metabolic proﬁle between
species was observed.
Human studies: These experiments have been conducted and
could also be used following the roadmap: because of the history of
human use, it would not be unethical to conduct these single dose
studies without in vivo animal studies, except with regard to potential
allergenicity:
Regarding possible allergenicity of stevioside: available data con-
cerning anaphylaxis-like reactions by stevioside in children with
atopic eczema do not raise concern regarding the potential for oral
exposure to steviol glycosides to trigger anaphylactic reactions.
Sparse in vitro and in vivo data indicate that stevioside may have
immunostimulating effects and modulatory activities on inﬂam-
mation. Immunostimulating and immunomodulating effects of
steviol glycosides in cell lines and rodent models have not been
demonstrated in a robust and reproducible way, which could
enable them to be used as pivotal studies for risk assessment. These
observations deserve more in-depth examination as, if they are
conﬁrmed, they may raise concern regarding the use of steviosides
in some sub-groups of the population, particularly for individuals
suffering from auto-immune diseases or inﬂammation of the
gastrointestinal tract.
In human volunteers exposed orally (dose ranging from 375 to
750 mg/day) to stevioside or rebaudioside A, no free steviol was
detected in the blood but steviol glucuronide was found to be the
main metabolite in plasma. No steviol epoxide, which may be
mutagenic, was detected in human plasma. Steviol glucuronide
appeared in the plasma after administration of rebaudioside A or
stevioside, with median plasma peak time values of 12 and 8 h
post-dose, respectively. In both cases, two plasma peaks occurred at
6e12 and 24 h post-dose. Steviol glucuronide was eliminated from
the plasma, with similar half-life values of approximately 14 h for
both compounds. The presence of multiple peaks in time of plasma
concentrations of steviol glucuronide indicates enterohepatic cir-
culation of steviol in humans. Steviol glucuronidewas also reported
to be the main metabolite found in the urine of subjects receiving
stevioside or rebaudioside A; this elimination pathway accounted
for about 60% of the dose. Steviol was reported to be the main
metabolite found in the faeces of humans receiving oral stevioside
or rebaudioside A. Steviol glucuronide is excreted primarily via the
urine in humans.
Box 4. Exposure estimates.
Structural alerts should be addressed ﬁrst, since the exposure is
estimated to be considerable. TTC approach is therefore not appli-
cable. Small children and adults are both part of the target
population.
The dietary exposure to steviol glycosides (E 960) ranges for
toddlers from 2.0 to 4.3 mg/kg bw/day at the 95th percentile. The
exposure levels for children are estimated to be between 1.3 and
3.9 mg/kg bw/day at the 95th percentile. Exposure estimates
calculated for adolescents of 0.6e1.8 mg/kg bw/day for high level
exposure. In adults, the exposure levels are up to 2.2 mg/kg bw/day
at the high exposure levels. In the elderly, the high exposure level is
estimated up to 1.3 mg/kg/bw.
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Test metabolic ceacal fractions in in vitro genotox assays (Ames,
chromosomal abb.), although from human ADME studies it is
demonstrated that possible genotoxic metabolites are absent from
the systemic circulation, site of contact tissue (GIT) should be
looked at.
Steviol and some of its oxidative derivates showed clear evi-
dence of genotoxicity in vitro, particularly in the presence of a
metabolic activation system.
Box 10, 11, 12. Extrapolation in vitro dose to in vivo human dose and
risk assessment.
Randomised, placebo controlled clinical trials were conducted
to study the effect of steviol glycosides on glycemic response. Single
doses of 1000 mg steviol glycosides/person/day (97% rebaudioside
A) corresponding to approximately 330mg steviol equivalents/day)
did not affect glucose homeostasis and did not affect blood pressure
in individuals with normal glucose tolerance or type-2 diabetes
mellitus. Also repeated use for 16weeks of 1000mg rebaudioside A/
person/day did not alter glucose homeostasis in individuals with
type-2 diabetes mellitus. Blood pressure parameters were not
signiﬁcantly affected by oral intake of 1000 mg rebaudioside A/
person/day for 4 weeks in individuals with normal and low systolic
blood pressure. This daily dose corresponds to 16.6 mg of rebau-
dioside A/kg bw for a person weighing 60 kg and to approximately
5.5 mg steviol equivalents/kg bw/day.
In conclusion, while following the roadmap and disregarding all
existing in vivo information on steviosides: the human kinetics of
steviosides are well addressed using the in vitro systems making
use of human enzymes and enzymes of different animal species. No
species difference was observed, and in humans the glucur-
onidation of steviol appears the main metabolic pathway, also
supported by in vivo human data.
Further in vitro investigations also pointed towards clear evi-
dence of genotoxicity of steviol and some of its oxidative derivates,
particularly in the presence of a metabolic activation system and
towards potential immunomodulating properties. With regard to
the possible genotoxic potential especially site of contact tissue
(GIT) should be further investigated, since systemically the glu-
curonidation does not appear to be saturated at relevant levels of
exposure. It should be investigated if relevant in vitro models are
available and how do these translate to the human situation.
In addition regarding the target population including pregnant
and lactating women and small children, speciﬁc endpoints on
reproduction toxicity and teratogenicity should be addressed.
Currently no in vitromodels are available replacing the established
in vivo animal models.
8.2. Case 2: synthetic lycopene
This case study is based on a proposal for the use of synthetic
(crystalline) lycopene as a food ingredient/food supplement which
was reviewed by EFSA (EFSA Journal, 2008). The question that was
addressed was ‘Is the synthetic (crystalline) lycopene safe to use by
the general population at levels of 8 or 15 mg/dosing in supple-
ments, at levels up to 2.5 mg/100 g in beverages and dairy products,
up to 4 mg/100 g in breakfast cereals, up to 8 mg/100 g in cereal
bars?’.
For the safety assessment of synthetic lycopene the approach
taken was to compare the synthetic lycopene with naturally
occurring lycopene (from tomatoes and tomato products) to
determine if a read across approach could be taken based onchemical similarity or, if there were any differences, were there any
components of concern. This was followed by a comparison of the
human exposures that could result when using synthetic lycopene
and whether this is qualitatively and quantitatively similar to what
is already occurring with the uses of natural lycopene.
Following Fig. 1 the relevant questions are addressed:
Box 1. Intended Use; Food Application; Use levels; Target
population.
The novel food ingredient consists of synthetic (crystalline)
lycopene to be marketed in three different formulations. These are
lycopene 10%, lycopene 10 cold water dispersion (CWD) and lyco-
pene dispersion 20%. Synthetic lycopene will be used in food sup-
plements at levels of 8 or 15 mg/dosing, in beverages and dairy
products at levels of up to 2.5 mg/100 g, in breakfast cereals up to
4 mg/100 g, in cereal bars up to 8 mg/100 g, in fats and dressings up
to 4mg/100 g and also in dietary foods for special medical purposes
at levels suited to those that the products are relevant to. The target
population will include both adults and children.
Box 2. Provide information on physical chemical properties (incl.
solubility) and characterisation of the material: identiﬁcation of
(non)nutritional compounds. Include changes in composition due
to production process (impurities).
Lycopene is a carotenoid with the formula C40H56 (molecular
weight of 536.85 and CAS 502-65-8).
Lycopene occurs in food predominantly in an all-trans form
(Cronin, 2000; Boileau et al., 2002). Tomatoes and tomato products
contain the all-E (trans-)isomers of lycopene (between 35 and 96%
of total lycopene content), but also some Z (cis-)isomers, mainly as
5Z, 9Z, 13Z and 15Z in percentages varying between 1 and 22%
(Schierle et al., 1997).
Synthetic lycopene consist mainly of the all trans-lycopene
(>70%) with 5-cis-lycopene (max. 20%) and up to 3.5% other cis
isomers. It contains the same cis isomers found in tomatoes and
tomato products.
The synthetic lycopene considered in this case study included
other components in the speciﬁcation but thesewere all considered
to be standard food grade materials and therefore not of any safety
concern. However, for one of the proposed formulations (20%
dispersion) it was noted that no additional stabilisers were
included which might result in oxidation of the material. Speciﬁ-
cations were set for purity of >96% and for the presence of con-
taminants such as heavy metals.
There were no aspects of the production process that were
considered to add any safety concerns to the material.
Based on the comparison of the chemistry and any components
of concern the safety of synthetic lycopene can be based on simi-
larity to naturally occurring lycopene using a History of Safe Use
approach (Constable et al., 2007). Therefore next question to
consider in the roadmap would be Box 4.
Box 4. Exposure estimation.
It was estimated that intakes of lycopene from natural dietary
sources in different populations are, according to dietary surveys,
estimated to average between 0.5 and 5 mg/day, with high expo-
sures up to about 8 mg/day. High consumption of fruits and vege-
tables, especially tomato products, may result in occasional intakes
of 20 mg lycopene/day or more.
Intake of lycopene from supplements is not expected to be more
than 21 mg/day among supplement users, based on the combined
use of one lycopene supplement (providing maximal 20 mg of
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of lycopene).
Lycopene intake via lycopene fortiﬁed products is estimated to
be 28e30 mg/day for children up to 9y, 37 mg/day for males and
33 mg/day for females aged 10e18y, and 25 mg/day for males and
23 mg/day for females over 19y. Expressed per kg bw the estimated
95th percentile intakes will be highest for children (1e3y), being
2.2 mg/kg bw/day, intermediate for children (4e9y), 1.3 and 1.4 mg/
kg bw/day, for girls and boys respectively, and lowest for men and
women (19y) 0.32 and 0.35 mg/kg bw/day, respectively.
Overall intakes from the proposed uses of synthetic lycopene
would lead to intakes substantially higher than dietary intake of
lycopene, and could lead to daily intakes from 10.5 to 30 mg/day at
the mean and to 52e95 mg/day as high intakes. These values
amount from 0.175 to 0.5 mg/kg bw/day and 0.87e1.58 mg/kg bw/
day for a 60 kg person and are for the high intake estimates sub-
stantially higher than the ADI recently established by the AFC Panel
as a group ADI of 0.5 mg/kg bw/day for lycopene from all sources
(EFSA, 2008). This ADI is in line with the ADI of 0e0.5 mg/kg bw/
day established by JECFA (JECFA, 2006).
It was concluded that intakes at the average level are in linewith
the ADI but there may be some excursions above this in high level
consumers.
Box 10. Measure the real exposure and ADME, speciﬁcally for target
groups such as children, elderly and obese population.
Lycopene absorption from puriﬁed or synthetic lycopene has
been demonstrated to be comparable to tomato-based lycopene
(Hoppe et al., 2003). In a study in healthy adults synthetic and
tomato-lycopene resulted in signiﬁcant increases above baseline of
serum total lycopene by 0.58 and 0.57 micro mol/L, trans-lycopene
by 0.34 and 0.41 micro mol/L, and total-cis-lycopene by 0.24 and
0.16 micro mol/L, whereas no signiﬁcant changes were found in the
placebo treatment. The mean serum total lycopene response to
synthetic and natural lycopene was not signiﬁcantly different.
Interactions, both competitive and synergistic, between carot-
enoids have been shown to occur during the various stages of ab-
sorption (e.g., incorporation into mixed micelles, intracellular
transport within enterocytes, and chylomicron assemblage), as well
as during post-absorptive distribution (Furr and Clark, 1997; Van
den Berg, 1999). However, the mechanisms via which this occurs
are not clear, and deﬁnite relationships between speciﬁc caroten-
oids have not been established. The speciﬁc carotenoids in the
synthetic lycopene are comparable with the natural lycopene and
therefore interactions are not expected. However, it may be pru-
dent to consider a study to investigate uptake of individual com-
ponents from the synthetic lycopene to ensure they are within
those of natural lycopene.
Little is known about metabolism and degradation of lycopene
in mammals but it would not be expected that this would differ
between the synthetic and natural lycopene based on their similar
structure. Analysis of lycopene metabolism and degradation could
be made as part of a human study.
Box 12. Perform risk assessment, determine safety levels and hu-
man ADI or reference daily intake (RDI) for general public and
target groups.
An ADI of 0e0.5 mg/kg bw/day was established by JECFA (JECFA,
2006) for lycopene from all sources.
There are numerous published short-term and sub-chronic
toxicity studies on natural and other synthetic lycopene mate-
rials. These have been summarised as part of a review by EFSA on
lycopene as a colour (EFSA, 2008). These conﬁrmed the basis of theADI set by JECFA using a NOAEL in a 1 year rodent study of 50 mg/
kg/day. It was conﬁrmed that there might be higher intakes on
occasions which would exceed the ADI. However, there would be
no difference expected in the safety proﬁle of the novel synthetic
lycopene with natural or synthetic lycopene already in use and
therefore no further work would be required.
8.3. Case 3: botanical extracts as beverages
The majority of our foods are complex materials, and not single
molecular entities. The ﬁrst two cases considered are examples of
well-deﬁned single molecules, or fairly well characterised simple
mixtures, used as additives, or ingredients into a wide variety of
foods. More challenging in the context of this present discussion is
how to assess the safety of complex mixtures, such as actual foods.
Botanicals such as traditional herbal medicines, is an area which
receives a lot of attention. The applicability and availability of in
silico methodologies and phytochemical data sources were
reviewed by Barlow et al. (2012). Pelkonen et al. (2012) discussed
the potential impact of omics techniques on R&D and regulation of
complex herbal products, and propose using omics techniques and
a systems biology approach to integrate data from in vitro and
in vivo tests, preclinical and clinical toxicity, pharmacokinetics,
pharmacodynamics and efﬁcacy tests. Current and new (alterna-
tive) methods for assessing genotoxicity, teratogenicity and neph-
rotoxicity of herbal medicines and mushrooms have been reviewed
(Ouedraogo et al. 2012). For example, useful in vitromethodologies
for teratogenicity, covering all aspects of prenatal development are
available, however a major drawback is that the lack of placenta
means that real foetal exposure cannot be determined.
An appropriate example for the food industry to take is aqueous
botanical extracts which are consumed as beverages. Many com-
mon foods can be included in this class of products, such as coffee,
tea, herbal teas. The raw materials used to prepare the different
beverages can be different parts of plants (roots, leaves, ﬂowers,
fruit), and subjected to a variety of processing before being used to
prepare the water infusions which are consumed. Powdered ex-
tracts can also be prepared, which are added to water to prepare
‘instant’ beverages. As well as simple hot water infusions, organic
solvent extracts may be used if the aim is to enrich in certain
‘bioactives’. Such liquids which are to be consumed as such are also
more amenable to testing in in vitro assays, with potentially less
technical difﬁculties and bias than solid foods.
Booth et al. (2012) evaluated the safety of a cranberry leaf
extract. This is an example of a new food product, for which a
history of use is known for the fruit of the species, and is a common
food, but no knowledge exists on the safety of the leaves as
consumed. Based on literature search of suspected compounds, on
analytical proﬁling, on expected exposures and comparison to
health based reference values (TTC, extrapolation from animal
studies, ADIs etc.), no safety concern was identiﬁed in the study,
and no further requirements for further safety testing would likely
be needed before human consumption. This conclusion could be
further substantiated using the steps in our roadmap.
Problem formulation: ‘Are there indications for health concerns
from a beverage prepared from water extraction of Cranberry leaves?
Box 1. Intended Use; Food Application; Use levels; Target
population.
There is no history of use of the leaf of this plant species (Vac-
cinium macrocarpon), although there is a common use of the fruit
(cranberry). A powdered water extract is to be developed as an
ingredient for a new family of commercial beverages. The intended
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beverage, with a possible ingestion of 2 servings/day.
Box 2. Physical-chemical characterisation.
Literature search was performed on V. macrocarpon, extended to
other members of Vaccinium genus and Ericaceae family for po-
tential chemical components. These were grouped into classes of
compounds, with a reference indicator compound (as available) for
each class. It was acknowledged that appropriate standard oper-
ating procedures have to be developed to prevent contamination
with undesired species (weeds, and any associated toxins), and
authenticity purposes (HACCP, supply chain control).
Chemical analyses were performed on representative samples
(from different harvest seasons and locations) of plant leaf material.
Analyses included general parameters such as heavy metals, mi-
crobes, pesticides, ash content, % foreign material, % solids, mois-
ture content, water activity. Additionally, a screen was made for
organic compounds identiﬁed from literature to be of greatest
toxicological concern.
Compounds known to be of high toxicological concern such as
Ephidrene alkaloids, aristolocholic acid, gossypol, pyrrolidizine al-
kaloids, cardiac glycosides were not considered in this particular
case as these are found in unrelated plants.
Box 4. Exposure estimation.
Commercial (or batch scale) batches was prepared, standardised
on anthocyanin content of 33.4mg/8 oz. serving (approx. 250ml). It
was assumed that all compounds are 100% transferred into water
extract, and so 8 oz. servingwould be equivalent of consuming 2.4 g
dried leaf, 2 servings.
Box 12. Perform risk assessment.
It was evaluated whether consumer exposure to key phyto-
chemicals (e.g. arbutin, indole alkaloids, quinolizidine alkaloids,
grayanotoxins) is acceptable by using established Acceptable Daily
Intakes (ADIs), or establishing such reference values based on
available toxicity data, and comparing against Estimated Daily in-
takes (EDIs).
Based on the absence of compounds of high toxicological
concern, no alert for concern was identiﬁed, and product devel-
opment could continue.
To further strengthen the argument of absence of concern, some
in vitro assays could be performed for bioavailability, genotoxicity,
and liver toxicity. There would be a need to consider bacterial
metabolism in the gut as well as liver metabolites. If still no alerts
are identiﬁed, then there would be no requirement for an inte-
grated testing strategy. However, additional screening and an ITS
could be done if an incomplete characterisation was performed,
uncertainties remained, and if there were alerts for the presence of
compounds structurally related to known toxins. If from literature
searches case reports are found of health concern, then targeted
studies would be required to investigate such reports. For example,
as in the case of concentrated green tea extract, liver toxicities have
been reported. This could then indicate ITS concentrating on liver
toxicity.
8.4. Case 4: Cetyl Myristoleate Complex (CMC)
Cetyl Myristoleate Complex (CMC) is a powder consisting of
cetylated fatty acids (CFAs), and an application made in Europe
through the Novel foods regulation. EFSA have evaluated this
complex several times (EFSA, 2010, 2013; 2014), each timeconcluding that the safety of the CMC had not been established. The
major concerns of the EFSA Dietetic Products, Nutrition and Al-
lergies (NDA) Panel were that in the absence of data on the ab-
sorption, distribution, metabolism and excretion of unhydrolysed
CFAs, that the existing toxicological data was not adequate.
The applicant provided data from literature on the ADME of
CFAs. They proposed that CFAs in the CMC complex are expected to
be nearly completely absorbed. Most of the CFA will be hydrolysed
into cetyl alcohol and fatty acids. Cetyl alcohol is then oxidised to
palmitic acid and esteriﬁed to phospholipids, triglycerides and
cholesterol esters. However, the material tested in the studies were
not considered to be representative of the CMC for which the
application had been made, and it appears that a small amount of
intact unhydrolysed CFAs (approx. 10%) remained in various organs
of the body. The panel considered that the existing informationwas
not sufﬁcient to determine the ADME of the remaining intact CFAs.
An acute LD50 toxicity study with cetylated myristoleate was
submitted, but such studies are of limited value for assessing food
ingredients. Otherwise, only limited human trial data were avail-
able. Further data were supplied by the applicant, namely a dedi-
cated 90 day toxicological study. Although a NOAEL of 1000 mg/
kg bw/day was identiﬁed, the highest dose tested, the NDA panel
saw too many shortcomings in the experimental design and
execution of the study. A study report on the in-vitro hydrolysis of
cetyl myristoleate and cetyl myristate demonstrated a low rate of
hydrolysis in simulated digestive ﬂuids. This only re-iterated the
request from the panel for more safety information on unhy-
drolysed CFAs.
Question Formulation: How can the safety of CMC, with speciﬁc
focus on the ADME of unhydrolysed CFAs, be best assessed? Are
there adequate in silico/in vitro assays that could substitute for
better performed in vivo data?
Speciﬁcations indicate that CMC contains 48% oil which is
composed of 38% cetyl myristoleate (C14:0, Hexadecyl ester of
tetradecanoic acid), 40% cetyl myristate (C14:1, hexadecyl ester of
tetradecenoic acid), with 10% CFAs with Carbon chain of >C14:0,
and 10% with >C14:0. The rest of the CMC is cornstarch (48%) and
2% silicon dioxide. Analyses for heavy metals, dioxins, PCBs, PAHs
and pesticides did not indicate any concern. Microbial analyses
were compliant to the respective EC regulations.
A daily dose of 3.3 g CMC, corresponding to 1.65 g cetylated fatty
acids, with 660 mg cetyl myristoleate and cetyl myristate.
9. Conclusions and recommendations
This paper described the developments in the ﬁelds of toxi-
cology and risk assessment, which areas are undergoing an
extensive shift in the paradigms governing the experimental and
evaluation work that is the basis of evaluating the safe use of
chemicals and products in general. This shift was well-covered in
the 2007 NRC report (NRC, 2007) and can be summarised as a
departure from the emphasis on animal model-based evaluations
of apical endpoints of toxicity towards an approach that is more
focused on mechanisms of toxicity, kinetic knowledge of internal
exposure andmodelling methods. In line with these developments,
the possibilities to implement these new approaches in the ﬁeld of
foods and food ingredients were evaluated, also in the light of the
need to evaluate novel foods. A roadmap is described consisting of a
stepwise evaluation of the different aspects needed for a safety
evaluation. These steps consider e.g. the possible exposure sce-
narios, kinetics to evaluate the internal exposure, methods to
evaluate (target-speciﬁc) toxicities, mechanisms of toxicity, in vi-
tro/in vivo evaluations, as well as considerations of the beneﬁts vs.
the risk of adversity.
On the basis of thee limited number ofe cases described above,
B.J. Blaauboer et al. / Food and Chemical Toxicology 91 (2016) 19e35 33it is concluded that the use of the roadmap can be very helpful in
concluding on safety issues with regard to the substances described
in the cases, while avoiding the classical animal-based methods for
such safety evaluations as much as possible. However, in some
instances the use of animal models may still be required for
addressing particular questions, for example in developmental
toxicity.
Similar activities have been carried out with other categories of
chemicals, e.g. in the ILSI-HESI Risk-21 project (Pastoor et al., 2014;
Simon et al., 2014). A focus on food safety was recently described by
Schilter et al. (2014).
However, morework needs to be done to expand the experience
with the roadmap and the knowledge about the suitability and
applicability of available in vitro and in silico test systems in the
context of food safety assessment. The selected cases appeared to
be rather data rich, it will be clear that for many substances further
experimental work making use of e.g. in vitro systems, kinetic
models, etc. will be necessary. The tool described in the roadmap
can then be of help in selecting the (battery of) experimental sys-
tems needed to come to a conclusion. It is highly recommended to
invest in work testing this approach.
On the basis of this, the following recommendations for the
stakeholder parties in this area of safety evaluation can be made.
1. Gaps in our knowledge should be addressed. One gap is the
applicability of a number of the in vitromethods for the ﬁeld of
foods and food ingredients. This applies for example on the use
of in silico and in vitro data for oral absorption, for biotransfor-
mation and elimination as well as the applicability of many of
the methods described for more complicated mixtures and food
matrices.
2. Cooperation with other sectors such as pharma, chemical use,
pesticides. In these areas also evaluation schemes based on
newer paradigms are under development or highly needed (e.g.
Toxcast, Risk21, EUToxRisk).
3. There is a need to extend the practical applicability of the
roadmap presented here by taking up more case studies. The
formation of a task force of stakeholders and supported by ex-
perts in these applications can be a tool.
4. The further development of the Threshold of Toxicological
Concern (TTC), with emphasis on internal rather than external
exposure should be made applicable to the area of foods and
food ingredients.
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